Statin-treated individuals with elevated triglyceride-rich lipoprotein cholesterol (TRL-C) may be more likely to benefit from additional fibrate treatment, according to results of a study of 67,662 statin-treated adults without baseline atherosclerotic cardiovascular disease (ASCVD) from the Korean National Health Insurance Service cohort.
